| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2040.7B | ¥1937.4B | +5.3% |
| Operating Income | ¥194.9B | ¥186.1B | +4.7% |
| Ordinary Income | ¥239.9B | ¥217.6B | +10.3% |
| Net Income | ¥170.8B | ¥146.2B | +16.8% |
| ROE | 9.0% | 8.5% | - |
FY2025 Q3 results: Revenue 204.1B yen (+5.3% YoY), Operating Income 19.5B yen (+4.7% YoY), Ordinary Income 24.0B yen (+10.3% YoY), Net Income 17.1B yen (+16.8% YoY). Gross profit margin improved to 36.8%, driving profitability expansion. Operating cash flow surged +130.4% YoY to 13.1B yen though free cash flow remained negative at -7.2B yen due to substantial capital investments of 17.7B yen. Total assets increased to 488.9B yen with equity ratio at 38.8%, reflecting ongoing balance sheet expansion. EPS grew to 347.01 yen (+16.8% YoY). Revenue and profit growth continued, supported by domestic segment strength and favorable non-operating items including foreign exchange gains.
Revenue increased 10.3B yen (+5.3% YoY) to 204.1B yen, primarily driven by domestic segment expansion. Cost of sales rose to 128.9B yen, but gross profit improved to 75.1B yen with margin expanding to 36.8% from prior period levels, indicating improved pricing power or favorable product mix. SG&A expenses increased to 55.6B yen (27.3% of revenue), slightly higher than prior period ratio, but operating leverage remained positive as operating income grew 0.9B yen (+4.7%) to 19.5B yen with operating margin at 9.6%.
Non-operating income contributed significantly with net non-operating gains of approximately 4.5B yen, substantially higher than prior period. This comprised foreign exchange gains of 0.7B yen, equity in earnings of affiliates, and financial income. Non-operating income of 6.3B yen exceeded non-operating expenses of 1.8B yen (primarily interest expense of 1.7B yen), lifting ordinary income to 24.0B yen (+10.3% YoY). The 4.5B yen gap between operating income (19.5B yen) and ordinary income (24.0B yen) represents 23% uplift, indicating material contribution from non-operating factors.
Extraordinary items were minimal at 0.1B yen gain on asset sales offset by 0.1B yen impairment loss and 0.0B yen securities valuation loss, resulting in negligible net extraordinary impact. Income tax expense of 6.9B yen represented an effective tax rate of 28.7%. Net income reached 17.1B yen (+16.8% YoY), with net margin improving to 8.4%.
This represents a revenue up/profit up pattern, with bottom-line growth (+16.8%) outpacing top-line growth (+5.3%) due to margin expansion and favorable non-operating items.
Domestic segment generated revenue of 163.8B yen (80.2% of total revenue) and operating income of 22.8B yen with margin of 13.9%, representing the core business. Domestic revenue increased 5.9% YoY from 154.7B yen, with operating income improving 2.2% from 22.3B yen.
Overseas segment contributed revenue of 40.3B yen (19.8% of total) and operating income of 0.0B yen with margin of 0.1%, recovering from prior period operating loss of -0.4B yen. Overseas revenue grew 3.3% YoY from 39.0B yen. The dramatic margin differential between domestic (13.9%) and overseas (0.1%) segments highlights the profitability concentration in domestic operations and ongoing challenges in achieving overseas profitability.
Corporate adjustments of -3.3B yen primarily reflect goodwill amortization of -3.4B yen, consistent with prior period adjustment of -3.3B yen. The overseas segment's return to marginal profitability after prior period losses represents a notable inflection point, though absolute profit contribution remains minimal.
[Profitability] ROE 9.0% reflects moderate return on equity, supported by net profit margin of 8.4% and operating margin of 9.6%. Gross profit margin of 36.8% indicates solid pricing power. ROA of 3.5% (annualized from 9-month net income against total assets) reflects moderate asset utilization. [Cash Quality] Cash and deposits of 39.8B yen cover short-term liabilities with ratio of 7.03x, indicating strong immediate liquidity. Operating cash flow of 13.1B yen represents 0.77x coverage of net income, below the 0.8x benchmark threshold, suggesting some earnings quality concerns related to working capital consumption. [Investment Efficiency] Asset turnover of 0.42 (annualized revenue of 272B yen divided by total assets 488.9B yen) indicates capital-intensive operations. ROIC of approximately 4.0% (operating income after tax divided by invested capital) suggests room for improvement in capital efficiency. [Financial Health] Equity ratio 38.8% indicates moderate financial stability. Current ratio of 283.5% reflects strong short-term solvency. Debt-to-equity ratio of 1.02 (interest-bearing debt 194.1B yen against equity 189.7B yen) shows moderate leverage. Net debt-to-EBITDA of approximately 5.9x indicates elevated debt burden relative to cash generation capacity.
Operating cash flow of 13.1B yen represents 0.77x of net income, indicating modest cash conversion with working capital consuming approximately 3.9B yen in cash. Operating cash flow before working capital changes reached 22.9B yen, reflecting strong underlying earnings quality. Major working capital movements included inventory increase of -11.1B yen consuming cash as the company built stock, receivables increase of -8.2B yen from revenue growth outpacing collections, and payables increase of 0.7B yen providing minor cash inflow. Income taxes paid of -8.5B yen and interest paid of -1.6B yen represented significant cash outlays. Investing cash flow of -20.3B yen was primarily driven by capital expenditures of -17.7B yen, substantially exceeding depreciation and amortization of 13.4B yen by 1.32x, indicating growth investment phase. Financing cash flow of 0.1B yen was near neutral. Free cash flow of -7.2B yen (operating CF 13.1B yen minus investing CF -20.3B yen) indicates net cash consumption, requiring either cash reserves drawdown or external financing to fund the investment program. Interest and dividends received of 0.2B yen provided minor supplementary cash inflow.
Ordinary income of 24.0B yen versus operating income of 19.5B yen shows non-operating net contribution of approximately 4.5B yen, representing 23% uplift to operating profit. This comprises primarily foreign exchange gains of 0.7B yen, other non-operating income of 0.7B yen, and interest income of 0.2B yen, partially offset by interest expense of 1.7B yen. Non-operating income represents 3.1% of revenue, consisting of interest and dividend income of 0.2B yen and FX gains of 0.7B yen. The FX gains are potentially volatile and non-recurring in nature, suggesting caution in projecting ordinary income sustainability. Operating cash flow of 13.1B yen fell short of net income of 17.1B yen by 0.77x coverage ratio, indicating working capital consumption impaired cash generation. The primary accruals concern stems from inventory build of -11.1B yen and receivables increase of -8.2B yen, which absorbed cash despite profit growth. Comprehensive income of 22.0B yen exceeded net income by 4.9B yen due to foreign currency translation adjustments of 4.8B yen, suggesting unrealized gains from overseas operations. Overall earnings quality shows mixed signals: core operating profit is sustainable, but reliance on non-operating FX gains and working capital consumption warrant monitoring.
Full-year guidance targets revenue of 280.0B yen and operating income of 27.0B yen. Q3 cumulative results show revenue progress of 72.9% and operating income progress of 72.2% against full-year targets. With three quarters (75% of year) completed, both revenue and operating income progress rates are slightly behind the 75% standard by approximately 2-3 percentage points, indicating the company is tracking slightly below linear run rate. This minor shortfall suggests Q4 requires acceleration to meet full-year guidance, though the gap is within normal quarterly volatility range. Ordinary income guidance of 25.3B yen implies Q3 progress of 94.9%, substantially ahead of schedule, reflecting the strong non-operating income contribution in first nine months. Net income guidance implies annual EPS of 359.57 yen. No forecast revision was announced this quarter, indicating management confidence in achieving targets despite modest Q4 acceleration requirement. The forecast assumes continued domestic segment strength and stabilization of overseas operations.
Annual dividend forecast is 40.00 yen per share, unchanged from prior guidance. Based on forecast EPS of 359.57 yen, the payout ratio is 11.1%, indicating conservative dividend policy with substantial retained earnings for reinvestment. Comparing to actual Q3 cumulative EPS of 347.01 yen annualized, the implied payout ratio would be approximately 11.5%. No share buyback activity was disclosed during the period. Total shareholder return ratio remains at 11.1% (dividends only), well below typical target ranges of 30-50%, suggesting management prioritizes internal investment and balance sheet flexibility over shareholder distributions. The low payout ratio provides ample buffer for dividend sustainability even if earnings face headwinds. However, with free cash flow negative at -7.2B yen, dividend payments would require funding from existing cash reserves or debt, highlighting cash flow strain despite accounting profitability.
Working capital efficiency deterioration poses ongoing cash flow risk, with inventory increasing 11.1B yen and receivables rising 8.2B yen consuming 19.3B yen in operating cash during the nine-month period. Inventory turnover days of approximately 142 days and receivables turnover days of approximately 126 days indicate extended cash conversion cycles. If working capital trends continue, the company may face persistent negative free cash flow requiring external financing.
High financial leverage with net debt-to-EBITDA of 5.9x and debt-to-equity of 1.02 creates vulnerability to interest rate increases and refinancing risk. Interest-bearing debt of 194.1B yen against EBITDA of approximately 32.8B yen (operating income 19.5B yen plus D&A 13.4B yen) indicates elevated debt burden. Rising interest rates could materially increase interest expense of 1.7B yen, pressuring profitability.
Overseas segment profitability remains fragile at 0.1% margin despite recent recovery from losses. With 19.8% of revenue from overseas generating minimal profit contribution, the company faces structural challenges in achieving profitable international expansion. Failure to improve overseas margins would limit growth potential and perpetuate domestic market dependence.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating Margin 9.6% substantially outperforms industry median of -218.2% (IQR: -628.8% to -14.9%), placing the company in the top quartile. ROE of 9.0% significantly exceeds industry median of -35.8% (IQR: -91.4% to -6.1%), indicating superior profitability versus loss-making peer group. Net profit margin of 8.4% substantially outperforms industry median of -216.8%.
Financial Health: Equity ratio of 38.8% falls below industry median of 67.8% (IQR: 62.1% to 79.1%), indicating higher leverage than typical pharmaceutical peers. Current ratio of 283.5% falls below industry median of 662% (IQR: 466% to 918%), though still reflects adequate liquidity. Net Debt/EBITDA of 5.9x exceeds industry median of 1.5x (IQR: 0.6x to 4.0x), placing the company in the higher leverage quartile.
Efficiency: Asset turnover of 0.42 exceeds industry median of 0.17 (IQR: 0.05 to 0.24), indicating superior capital efficiency. ROIC estimate of 4.0% substantially exceeds industry median of -0.32 (IQR: -1.45 to -0.02). Operating working capital cycle management shows room for improvement relative to industry dynamics.
Growth: Revenue growth of 5.3% significantly outperforms industry median of -12.5% (IQR: -22.1% to -2.5%), placing the company among growth leaders. EPS growth of 16.8% substantially exceeds industry median of -6% (IQR: -55% to 27%).
The company demonstrates exceptional profitability and growth relative to a pharmaceutical industry benchmark group experiencing widespread losses, but maintains higher financial leverage and lower equity cushion than typical peers.
(Industry: Pharmaceuticals, Comparison: FY2025-Q3, Source: Proprietary analysis)
Revenue and profit growth momentum continues with domestic segment driving performance at 13.9% operating margin, while overseas operations achieved inflection point returning to marginal profitability after prior losses. The 5.3% revenue growth and 16.8% net income growth demonstrate operating leverage benefits as the company scales.
Cash flow quality concerns emerge from operating CF coverage of 0.77x net income falling below the 0.8x threshold, coupled with substantial working capital consumption of 19.3B yen from inventory and receivables build. Free cash flow of -7.2B yen despite 17.1B yen net income highlights the gap between accounting profitability and cash generation, creating tension between investment requirements and shareholder distributions.
Financial leverage metrics warrant monitoring with net debt-to-EBITDA of 5.9x substantially exceeding industry median of 1.5x and approaching high-yield debt territory. The 11.1% payout ratio provides dividend sustainability cushion from earnings perspective, but negative free cash flow means dividends require funding from cash reserves or incremental borrowing. Capital allocation priorities favor growth investment with CapEx of 17.7B yen exceeding depreciation by 1.32x, indicating the company is in expansion phase requiring careful balance between growth investment, debt management, and shareholder returns.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.